SEC Company Response from Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554) (MTNB) — Jul 21, 2015
Matinas BioPharma Holdings, Inc. (MTNB) (CIK 0001582554)
Date: July 21, 2015 · CIK: 0001582554 · Accession: 0001144204-15-043429
AI Filing Summary & Sentiment
File numbers found in text: 333-204825
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attn: Tara Keating Brooks Re: Matinas BioPharma Holdings, Inc. Registration Statement on Form S-1 (File No. 333-204825)
Dear Mr. Foley:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-204825) (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:00 p.m., Eastern Standard Time, on Thursday, July 23, 2015, or as soon as practicable thereafter.
In connection with the acceleration of the Registration Statement, the Company hereby acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
MATINAS BIOPHARMA HOLDINGS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Matinas BioPharma Holdings, Inc.
1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
July 21, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attn: Tara Keating Brooks
Re: Matinas BioPharma Holdings, Inc.
Registration Statement on Form S-1 (File
No. 333-204825)
Dear Mr. Foley:
In accordance with
Rule 461 under the Securities Act of 1933, as amended, Matinas BioPharma Holdings, Inc. (the “Company”) hereby
requests that the above-referenced Registration Statement on Form S-1 (File No. 333-204825) (the “Registration Statement”)
be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:00 p.m., Eastern Standard Time,
on Thursday, July 23, 2015, or as soon as practicable thereafter.
In connection with
the acceleration of the Registration Statement, the Company hereby acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness of the Registration
Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United
States.
Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to
confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
MATINAS BIOPHARMA HOLDINGS, INC.
By:
/s/ Jerome Jabbour
Name: Jerome Jabbour
Title: EVP, Chief
Business Officer and General Counsel